Clinical characteristics of grade 3 follicular lymphoma patients with 100% follicular lymphoma (FL) and those with diffuse areas (DFL)
| . | FL (%) . | DFL (%) . | P . |
|---|---|---|---|
| Total number | 118 (62) | 72 (38) | |
| Sex | |||
| Male | 50 (42) | 38 (53) | .18 |
| Female | 68 (58) | 34 (47) | |
| Age, y | |||
| Median | 61 | 63 | .72 |
| Range | 33-86 | 16-85 | |
| Stage | |||
| I/II | 30 (27) | 32 (48) | .0054 |
| III/IV | 82 (73) | 34 (54) | |
| B symptoms | |||
| No | 88 (78) | 50 (75) | .72 |
| Yes | 25 (22) | 17 (25) | |
| Extranodal sites | |||
| Fewer than 2 | 106 (93) | 60 (91) | .77 |
| 2 or more | 8 (7) | 6 (9) | |
| Karnofsky score | |||
| Higher than 70 | 100 (90) | 61 (92) | .79 |
| 70 or lower | 11 (10) | 5 (8) | |
| LDH | |||
| Normal | 75 (71) | 45 (71) | 1.00 |
| High | 30 (39) | 18 (29) | |
| IPI risk group | |||
| Low (0-2) | 80 (80) | 47 (80) | 1.00 |
| High (3-5) | 20 (20) | 12 (20) |
| . | FL (%) . | DFL (%) . | P . |
|---|---|---|---|
| Total number | 118 (62) | 72 (38) | |
| Sex | |||
| Male | 50 (42) | 38 (53) | .18 |
| Female | 68 (58) | 34 (47) | |
| Age, y | |||
| Median | 61 | 63 | .72 |
| Range | 33-86 | 16-85 | |
| Stage | |||
| I/II | 30 (27) | 32 (48) | .0054 |
| III/IV | 82 (73) | 34 (54) | |
| B symptoms | |||
| No | 88 (78) | 50 (75) | .72 |
| Yes | 25 (22) | 17 (25) | |
| Extranodal sites | |||
| Fewer than 2 | 106 (93) | 60 (91) | .77 |
| 2 or more | 8 (7) | 6 (9) | |
| Karnofsky score | |||
| Higher than 70 | 100 (90) | 61 (92) | .79 |
| 70 or lower | 11 (10) | 5 (8) | |
| LDH | |||
| Normal | 75 (71) | 45 (71) | 1.00 |
| High | 30 (39) | 18 (29) | |
| IPI risk group | |||
| Low (0-2) | 80 (80) | 47 (80) | 1.00 |
| High (3-5) | 20 (20) | 12 (20) |
LDH indicates lactate dehydrogenase.